OSAH is the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma.
The company expects OSAH to become a standalone public company on a U.S. national stock exchange in the first half of 2026.
OS Therapies (OSTX) up 3% premarket.


















